ABT vs DXCM

Abbott Laboratories remains a highly stable and diversified global healthcare leader, further solidifying its position with the recent $23 billion Exact Sciences acquisition which boosts its cancer diagnostics segment and is expected to accelerate 2026 revenue growth. While the company demonstrates robust financial health, strong competitive moats (e.g., FreeStyle Libre), and strategic capital all...

Dexcom maintains its strong position as a market leader in the Continuous Glucose Monitoring (CGM) sector, driven by the ongoing global rollout of G7 and promising initial traction for Stelo in the Type 2 non-insulin market. The company showcases a clear strategic vision for significant Total Addressable Market (TAM) expansion, supported by robust R&D and regulatory expertise, solid financial heal...